Patents Examined by Nizal S. Chandrakumar
  • Patent number: 11779584
    Abstract: The disclosure relates generally to alpha polyglutamated pemetrexed, formulations containing liposomes filled with alpha polyglutamated pemetrexed, methods of making the alpha polyglutamated pemetrexed and liposome containing formulations, and methods of using polyglutamated alpha polyglutamated pemetrexed and liposome containing formulations to treat hyperproliferative disorders (e.g., cancer) and disorders of the immune system (e.g., an autoimmune disease such as rheumatoid arthritis).
    Type: Grant
    Filed: February 7, 2019
    Date of Patent: October 10, 2023
    Assignee: L.E.A.F. HOLDINGS GROUP LLC
    Inventors: Clet Niyikiza, Victor Mandla Moyo
  • Patent number: 11779016
    Abstract: The present invention relates to a solution for resisting destruction of living plants and a related method. A solution including a buffered amine oxide admixed with at least one material selected from the group consisting of insecticides and fungicides is applied to the living plant and provides a synergistically effective greater resistance to living plant deterioration than any of the individual buffered amine oxide, insecticides and fungicides achieve. A related method is disclosed.
    Type: Grant
    Filed: June 19, 2019
    Date of Patent: October 10, 2023
    Assignee: KOP-COAT, INC.
    Inventors: Ronald W. Clawson, Jr., Hans A. Ward, Kenneth A. Cutler, Cameron R. Scott
  • Patent number: 11780815
    Abstract: Disclosed herein, inter alia, are compositions and methods for inhibiting DNA2.
    Type: Grant
    Filed: October 29, 2021
    Date of Patent: October 10, 2023
    Assignees: City of Hope, California Institute of Technology
    Inventors: Binghui Shen, Judith Campbell, Li Zheng, Hongzhi Li, David Horne, Jun Xie, Kenneth Karanja
  • Patent number: 11780828
    Abstract: The invention provides a compound of formula (I): or a pharmaceutically acceptable salt, stereoisomer, solvate, or prodrug thereof, wherein R1-R6 have any of the values described in the specification, as well as compositions comprising a compound of formula (I). The compounds are useful as contraceptive agents.
    Type: Grant
    Filed: May 3, 2022
    Date of Patent: October 10, 2023
    Assignee: REGENTS OF THE UNIVERSITY OF MINNESOTA
    Inventors: Ingrid Gunda Georg, Narsihmulu Cheryala
  • Patent number: 11771703
    Abstract: The instant disclosure provides methods and compositions for the diagnosis, treatment and prevention of a TGF?2-associated disease, disorder and/or condition, including, e.g., Scleroderma, other fibrotic disease, grade 4 glioblastoma (GBM) and/or Primary Open-Angle Glaucoma (POAG). The disclosure further provides pharmaceutical compositions and kits for the diagnosis, treatment and prevention of TGF?2-associated diseases, disorders and/or conditions.
    Type: Grant
    Filed: March 16, 2018
    Date of Patent: October 3, 2023
    Assignee: The Johns Hopkins University
    Inventors: Harry C. Dietz, Joseph Shin
  • Patent number: 11760726
    Abstract: The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N?-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly thyroid cancer, prostate cancer, hepatocellular cancer, renal cancer, and non-small cell lung carcinoma. The crystalline solid forms can be used to make the L-malate salt of cabozantinib.
    Type: Grant
    Filed: March 25, 2021
    Date of Patent: September 19, 2023
    Assignee: Exelixis, Inc.
    Inventors: Dana T. Aftab, Nathan Guz, Stephen Lau, Noel Hamill, Tracy Walker, Jana Galbraith, Simon Yau, Khalid Shah
  • Patent number: 11752127
    Abstract: The present technology relates to a method for treating anxiety or an anxiety-related disorder in an animal subject, the method comprising administering an effective amount of cannabidiol (CBD) to the animal subject.
    Type: Grant
    Filed: March 31, 2020
    Date of Patent: September 12, 2023
    Assignee: VIRBAC CORPORATION
    Inventors: Justyna Kulpa, Dana M. Vaughn
  • Patent number: 11744896
    Abstract: Provided are CDK2-PROTAC compounds and pharmaceutical compositions thereof that can be used for specific degradation of the cyclin-dependent kinase 2 (CDK2) protein, for treatment of cancers and other CDK2 related diseases as well as for prevention and treatment of hearing loss.
    Type: Grant
    Filed: September 28, 2021
    Date of Patent: September 5, 2023
    Assignees: CREIGHTON UNIVERSITY, ST. JUDE CHILDREN'S RESEARCH HOSPITAL, INC. (TENNESSEE NOT FOR PROFIT CORPORATION)
    Inventors: Jian Zuo, Santanu Hati, Marisa Laura Zallocchi, Robert Hazlitt, Jaeki Min
  • Patent number: 11738054
    Abstract: In one aspect, a method of preconditioning stem cells comprising exposing stem cells to low dose radiation (LDR) is provided. In another aspect, a population of preconditioned stem cells is provided, wherein the population of 5 preconditioned stem cells is obtained by exposing stem cells to LDR. Uses of the preconditioned stem cells are also provided. In other aspects, the stem cells are muscle stem cells.
    Type: Grant
    Filed: July 20, 2018
    Date of Patent: August 29, 2023
    Assignee: ATOMIC ENERGY OF CANADA LIMITED/ENERGIE ATOMIQUE DU CANADA LIMITÈE
    Inventors: Dmitry Klokov, Soji Sebastian, Yevgeniya Le
  • Patent number: 11739103
    Abstract: The present disclosure provides processes for preparing a crystalline form of 3-((1R,3s,5S)-3-((7-((5-methyl-1H-pyrazol-3-yl)amino)-1,6-naphthyridin-5-yl)amino)-8-azabicyclo[3.2.1]octan-8-yl)propanenitrile and related intermediate compounds.
    Type: Grant
    Filed: October 7, 2021
    Date of Patent: August 29, 2023
    Assignee: Theravance Biopharma R&D LP, LLC
    Inventors: Norbert Kraut, Matteo Conza, Anja Huste, Vit Lellek, Bjorn Gielen, Christian Pater, Dimitar Filipov, Xiaojun Huang, Stephen Roseblade
  • Patent number: 11738089
    Abstract: Disclosed herein, are compositions comprising one or more molecular guidance system (MGS) peptides and a cytotoxic agent. Also described herein, are methods of administering the compositions to patients with cancer.
    Type: Grant
    Filed: July 10, 2018
    Date of Patent: August 29, 2023
    Assignee: SRI International
    Inventors: Kathlynn C. Brown, Curtis Allred, Michael McGuire
  • Patent number: 11739068
    Abstract: The invention provides new polymorphs of N-[(3-fluoro-4-methoxypyridin-2-yl)methyl]-3 -(methoxymethyl)-1-({4-[(2-oxopyridin-1-yl)methyl]phenyl}methyl)pyrazole-4-carboxamide and salts thereof, pharmaceutical compositions containing them and their use in therapy.
    Type: Grant
    Filed: October 20, 2021
    Date of Patent: August 29, 2023
    Assignee: KalVista Pharmaceuticals Limited
    Inventors: Haydn Beaton, David Malcolm Crowe, Hannah Joy Edwards
  • Patent number: 11731954
    Abstract: The present disclosure relates generally to compositions and methods for treating cancer and neoplastic disease. Provided herein are substituted pyridine derivative compounds, and compositions (including pharmaceutical compositions) that include these compounds. The subject compounds and compositions are useful for inhibition of at least one histone demethylase. Furthermore, the subject compounds and compositions are useful for the treatment of cancer or neoplastic disease, such as prostate cancer, breast cancer, bladder cancer, lung cancer, melanoma, retinoblastoma, or multiple endocrine neoplasia type 1.
    Type: Grant
    Filed: April 12, 2021
    Date of Patent: August 22, 2023
    Inventors: Young K. Chen, Michael Brennan Wallace
  • Patent number: 11731938
    Abstract: Some aspects provide novel dofetilide derivatives and pharmaceutical compositions containing the same that are useful as pharmaceutical agents in the treatment of supraventricular and ventricular arrhythmias.
    Type: Grant
    Filed: December 22, 2021
    Date of Patent: August 22, 2023
    Assignee: Academic Pharmaceuticals Inc
    Inventors: John Somberg, Robert J Chorvat
  • Patent number: 11730739
    Abstract: CRF1 receptor antagonists have the potential to directly inhibit ACTH release in patients with CAH and thereby allow normalization of androgen production while using lower, more physiologic doses of hydrocortisone, and thus reducing treatment-associated side effects.
    Type: Grant
    Filed: October 20, 2020
    Date of Patent: August 22, 2023
    Assignee: Neurocrine Biosciences, Inc.
    Inventor: Dimitri E. Grigoriadis
  • Patent number: 11724986
    Abstract: The invention relates to novel crystalline solid forms of the chemical compound N-{4-[(6,7-dimethoxyquinolin-4-yl)oxy]phenyl}-N?-(4-fluorophenyl) cyclopropane-1,1-dicarboxamide (Compound 1), and solvates thereof, including hydrates, that are useful for the treatment of cancer. Also disclosed are pharmaceutical compositions comprising the crystalline solid forms and processes for making the crystalline solid forms, as well as methods of using them for the treatment of cancer, particularly thyroid cancer, prostate cancer, hepatocellular cancer, renal cancer, and non-small cell lung carcinoma. The crystalline solid forms can be used to make the L-malate salt of cabozantinib.
    Type: Grant
    Filed: October 29, 2020
    Date of Patent: August 15, 2023
    Inventors: Dana T. Aftab, Nathan Guz, Stephen Lau, Noel Hamill, Tracy Walker, Jana Galbraith, Simon Yau, Khalid Shah
  • Patent number: 11725015
    Abstract: The present invention provides novel Compound (1) having tumor vascular remodeling effect and/or anti-CAF (Cancer Associated Fibroblasts) activity, or a pharmaceutically acceptable salt thereof, optionally in a pharmaceutically acceptable carrier, and medical uses thereof.
    Type: Grant
    Filed: February 4, 2021
    Date of Patent: August 15, 2023
    Assignees: President and Fellows of Harvard College, Eisai R&D Management Co., LTD.
    Inventors: Yoshito Kishi, Kazunobu Kira, Ken Ito
  • Patent number: 11724997
    Abstract: This disclosure features chemical entities (e.g., a compound or a pharmaceutically acceptable salt and/or hydrate and/or prodrug of the compound) that modulate (e.g., agonize) the apelin receptor (also referred to herein as the APJ receptor; gene symbol “APLNR”). This disclosure also features compositions containing the same as well as other methods of using and making the same. The chemical entities are useful, e.g., for treating a subject (e.g., a human) having a disease, disorder, or condition in which a decrease in APJ receptor activity (e.g., repressed or impaired APJ receptor signaling; e.g., repressed or impaired apelin-APJ receptor signaling) or downregulation of endogenous apelin contributes to the pathology and/or symptoms and/or progression of the disease, disorder, or condition.
    Type: Grant
    Filed: February 28, 2019
    Date of Patent: August 15, 2023
    Assignee: Annapurna Bio, Inc.
    Inventors: Haifeng Tang, Sarah Boyce, Michael Hanson, Zhe Nie
  • Patent number: 11718613
    Abstract: The present disclosure provides compounds having Formula I-A: and the pharmaceutically acceptable salts and solvates thereof, wherein A, X1, X2, X3 R1a, R1b, E, and are as defined as set forth in the specification. The present disclosure also provides compounds of Formula I-A for use to treat a disease, disorder, or condition responsive to Bcl-2 protein inhibition such as cancer.
    Type: Grant
    Filed: September 17, 2020
    Date of Patent: August 8, 2023
    Assignee: THE REGENTS OF THE UNIVERSITY OF MICHIGAN
    Inventors: Shaomeng Wang, Jianyong Chen
  • Patent number: 11718619
    Abstract: The disclosure relates to activators of FXR useful in the treatment of autoimmune disorders, liver disease, intestinal disease, kidney disease, cancer, and other diseases in which FXR plays a role, having the Formula (I): wherein L1, L2, A, B, R1, R2, R3, and R4 are described herein.
    Type: Grant
    Filed: April 7, 2021
    Date of Patent: August 8, 2023
    Assignee: Ardelyx, Inc.
    Inventors: Jianhua Chao, Rakesh Jain, Lily Hu, Jason Gustaf Lewis, Helene Baribault, Jeremy Caldwell